Juniper Pharma Services has entered into a long-term collaboration with OxSonics Ltd. to support the development, scale-up, and GMP manufacture of OxSonics’ sono-sensitive injectable particles.   When used in conjunction with new generation ultrasound devices, these injectable particles can be applied to a range of therapeutic applications including an oncological drug delivery platform called “SonoTran,” which is designed to enhance the delivery of anti-cancer drugs deep into solid tumors.  ...